News BI drug named Promising Innovative Medicine in mesothelioma Boehringer Ingelheim is the latest company to gain a Promising Innovative Medicine (PIM) status in the UK for one of its drugs.
News Immunocore’s rare cancer treatment gains UK Promising Medici... Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.
News Orchard’s gene therapy gains UK ‘promising innovative medici... A UK biotech start-up has gained a sought after ‘promising innovative medicine’ (PIM) designation for its ultra-rare disease gene therapy.
News Novartis drug gets 'Promising Innovative Medicine' status in... Novartis's cancer drug Zykadia has become one of the first drugs to snag Promising Innovation Medicine status in the UK's new early access scheme.
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.